STOCK EXCHANGE RELEASES

2026

09 Jan. 2025 Changes in the capital structure of J. Molner AS

2025

30 Dec. 2025 Additional increase of The J. Molner Company OÜ voluntary reserve

18 Dec. 2025 Increase of J. Molner share capital in connection with a capital structure adjustment transaction

5 Dec. 2025 Decisions of the shareholders - adoption of resolutions of the General Meeting without calling a meeting

25 Nov. 2025 J. Molner AS Announcement Regarding the Adoption of the Decisions of the Extraordinary General Meeting of Shareholders Without Calling the Meeting

14 Nov. 2025 J. Molner AS launches Clobetasol Propionate Cream USP, 0.05% (Emollient) in the United States

30 Sept. 2025 J. Molner AS 2025 6 months consolidated unaudited interim report

30 Sept. 2025 The subsidiary of J. Molner AS The J. Molner Company OÜ was granted an additional loan

1 Sept. 2025 J. Molner AS extension of Management Board Member terms of office

30 Jun. 2025 Additional increase of The J. Molner Company OÜ voluntary reserve

6 Jun. 2025 J. Molner announces changes in the management of The J. Molner Company LLC

22 May. 2025 Decisions of the shareholders - adoption of resolutions of the General Meeting without calling a meeting

5 May. 2025 Notice of J. Molner AS Regarding the Adoption of a Shareholders' Resolution Without Convening a General Meeting

25 Apr. 2025 Option Agreement Signed with Key Employee

21 Apr. 2025 J. Molner AS Audited Consolidated Annual Report 2024

28 Mar. 2025 J. Molner AS 2024 12 months consolidated unaudited interim report

13 Mar. 2025 J. Molner Strengthens U.S. Market Position with Strategic Generic Pharmaceutical Development Agreement

4 Feb. 2025 J. Molner AS launches Desoximetasone Ointment USP, 0.05% in the United States

2024

10 Dec. 2024 The subsidiary of J. Molner AS The J. Molner Company OÜ was granted an additional loan

10 Dec. 2024 J. Molner AS strengthens US market position with new product development agreement

4 Dec. 2024 J. Molner AS Announces Approval and Upcoming Market Launch of Desoximetasone Ointment USP, 0.05%

12 Nov. 2024 J. Molner AS launches Lidocaine HCL Topical Solution USP, 4% in the United States

22 Oct. 2024 J. Molner Announces New Chief Financial Officer

17 Sep. 2024 J. Molner AS Consolidated interim report for the first 6 months of 2024 (unaudited)

2 Sep. 2024 J. Molner Announces New President North America at The J. Molner Company LLC

28 Jun. 2024 Additional increase of The J. Molner Company OÜ voluntary reserve

21 Jun. 2024 Decisions of the shareholders - adoption of resolutions of the General Meeting without calling a meeting

5 Jun. 2024 J. Molner AS notice regarding the adoption of the decision of the general meeting of shareholders without calling the meeting 2023

30 Apr. 2024 J. Molner AS Gains US FDA Approval for First Estonian-Developed ANDA - Lidocaine Hydrochloride Topical Solution 4%

24 Apr. 2024 J. Molner AS Audited Consolidated Annual Report 2023

1 Apr. 2024 J. Molner AS Consolidated Unaudited Interim balance sheet for the 2 Months of 2024 and increase of The J. Molner Company OÜ voluntary reserve

28 Mar. 2024 J. Molner AS Consolidated Unaudited Interim Report for the 12 Months of 2023 and increase of The J. Molner Company OÜ voluntary reserve

4 Mar. 2024 J. Molner has entered into an agreement with the US Centers for Medicaid and Medicare Services (CMS)

10. Jan. 2024 The subsidiary of J. Molner AS The J. Molner Company OÜ was granted an additional loan

2023

15 Nov. 2023 J. Molner AS Enters the US Market with Hydrocortisone Butyrate Lotion, 0.1%

15 Sep. 2023 J. Molner AS Consolidated Unaudited Interim Report for the First 6 Months of 2023 and increase of The J. Molner Company OÜ voluntary reserve

6 Sep. 2023 J. Molner Signs Licensing Agreement for Five Approved Drugs in the US

2 Aug. 2023 Restructuring in the employee structure of J.Molner AS subsidiary The J. Molner Company OÜ

13 Jul. 2023 J. Molner submits drug application to U.S Food and Drug Administration (FDA)

8 Jun. 2023 J. Molner AS Announces Historic Milestone: Receives Health Canada Approval for its First Drug, Norepinephrine Bitartrate Injection

28 Apr. 2023 Restructuring in the employee structure of J.Molner AS subsidiary The J. Molner Company OÜ

20 Apr. 2023 J.Molner AS Resolutions of annual general meeting

10 Apr. 2023 J.Molner concludes loan agreement extending the existing credit facility of The J. Molner Company OÜ

6 Apr. 2023 J. Molner announces licensing agreement for generic injectable drugs with Juno Pharmaceuticals in Canada

28 Mar. 2023 Notice of calling the annual general meeting of the shareholders

28 Mar. 2023 J.Molner submits second drug to Health Canada

17 Mar. 2023 J.Molner AS comments on the observation status applied on J.Molner AS shares on March 10, 2023 by Nasdaq Tallinn

10 Mar. 2023 J.Molner AS Audited Annual Reports 2022

10 Mar. 2023 J.Molner AS Unaudited Interim Reports 2022

9 Jan. 2023 J. Molner AS executes planned reorganization transaction

2022

30 Nov. 2022 The first day of trading with new shares of J.Molner AS is 01.12.2022

14 Nov. 2022 FDA formally registers transfer to J. Molner AS of 3 drugs

7 Nov. 2022 Results of the initial public offering of J. Molner AS shares

27 Oct. 2022 J. Molner AS comment about the tenure of Jason Grenfell-Gardner at Teligent, Inc

24 Oct. 2022 Notice of initial public offering of J. Molner AS shares

19 Oct. 2022 Conditional admission to trading of J.Molner AS shares on Nasdaq Baltic Alternative market First North